Literature DB >> 30254230

Work Productivity and Activity Impairment in Irritable Bowel Syndrome (IBS): A Multifaceted Problem.

Åsa Frändemark1, Hans Törnblom1, Sofie Jakobsson1,1, Magnus Simrén1,1.   

Abstract

OBJECTIVES: Patients with irritable bowel syndrome (IBS) are more likely to be both absent from and impaired at work compared to non-IBS patients. We investigated the impact of IBS on work productivity and activity impairment and the relationship to disease specific and general health measures.
METHOD: In total, 525 patients with IBS completed questionnaires assessing work productivity and activity impairment, IBS symptom severity, IBS-related quality of life and GI-specific anxiety. In addition, 155 of the patients completed questionnaires assessing severity of somatic symptoms, depression, anxiety and fatigue. Uni- and bivariate analyses were performed, as well as linear regression to determine factors independently associated with the work productivity and activity impairment measures.
RESULTS: Of employed patients, 24.3% reported absenteeism and 86.8% reported presenteeism because of their IBS. With increasing severity of IBS symptoms and GI-specific anxiety, higher degrees of work impairment were seen. Work productivity impairment in IBS was also associated with low quality of life. GI-specific anxiety was independently associated with absenteeism (R2 = 0.23; p < 0.05), IBS-symptom severity and general fatigue with presenteeism (R2 = 0.40; p < 0.05), IBS-symptom severity, general fatigue and GI-specific anxiety with overall work loss (R2 = 0.50; p < 0.05), and IBS symptom severity and somatic symptoms with activity impairment (R2 = 0.38; p < 0.05).
CONCLUSION: Work impairment is a substantial problem in patients with IBS. A combination of IBS and somatic symptom severity, fatigue and psychological factors influence patients' ability to be present, active and productive at work. Based on this, a multidimensional treatment approach for patients with IBS seems logical.

Entities:  

Mesh:

Year:  2018        PMID: 30254230     DOI: 10.1038/s41395-018-0262-x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  36 in total

1.  Rational investigations in irritable bowel syndrome.

Authors:  Christopher J Black; Alexander C Ford
Journal:  Frontline Gastroenterol       Date:  2019-06-06

2.  Does Fibre-fix provided to people with irritable bowel syndrome who are consuming a low FODMAP diet improve their gut health, gut microbiome, sleep and mental health? A double-blinded, randomised controlled trial.

Authors:  Ran Yan; Mandy Murphy; Angela Genoni; Evania Marlow; Ian C Dunican; Johnny Lo; Lesley Andrew; Amanda Devine; Claus T Christophersen
Journal:  BMJ Open Gastroenterol       Date:  2020-08

3.  Effects of Irritable Bowel Syndrome on Daily Activities Vary Among Subtypes Based on Results From the IBS in America Survey.

Authors:  Sarah Ballou; Courtney McMahon; Ha-Neul Lee; Jesse Katon; Andrea Shin; Vikram Rangan; Prashant Singh; Judy Nee; Michael Camilleri; Anthony Lembo; Johanna Iturrino
Journal:  Clin Gastroenterol Hepatol       Date:  2019-08-13       Impact factor: 11.382

Review 4.  Genetics of irritable bowel syndrome: shifting gear via biobank-scale studies.

Authors:  Michael Camilleri; Alexandra Zhernakova; Isotta Bozzarelli; Mauro D'Amato
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-08-10       Impact factor: 73.082

5.  Mobile Apps for the Management of Gastrointestinal Diseases: Systematic Search and Evaluation Within App Stores.

Authors:  Eva-Maria Messner; Niklas Sturm; Yannik Terhorst; Lasse B Sander; Dana Schultchen; Alexandra Portenhauser; Simone Schmidbaur; Michael Stach; Jochen Klaus; Harald Baumeister; Benjamin M Walter
Journal:  J Med Internet Res       Date:  2022-10-05       Impact factor: 7.076

6.  Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment (The ATLANTIS trial): protocol for a randomised double-blind placebo-controlled trial in primary care.

Authors:  Sarah L Alderson; Alexandra Wright-Hughes; Alexander C Ford; Amanda Farrin; Suzanne Hartley; Catherine Fernandez; Christopher Taylor; Pei Loo Ow; Emma Teasdale; Daniel Howdon; Elspeth Guthrie; Robbie Foy; Matthew J Ridd; Felicity L Bishop; Delia Muir; Matthew Chaddock; Amy Herbert; Deborah Cooper; Ruth Gibbins; Sonia Newman; Heather Cook; Roberta Longo; Hazel Everitt
Journal:  Trials       Date:  2022-07-08       Impact factor: 2.728

Review 7.  Global burden of irritable bowel syndrome: trends, predictions and risk factors.

Authors:  Christopher J Black; Alexander C Ford
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-04-15       Impact factor: 46.802

8.  Effects of a comprehensive self-management intervention on extraintestinal symptoms among patients with IBS.

Authors:  Kendra J Kamp; Kristen R Weaver; LeeAnne B Sherwin; Pamela Barney; Sun-Kyung Hwang; Pei-Lin Yang; Robert L Burr; Kevin C Cain; Margaret M Heitkemper
Journal:  J Psychosom Res       Date:  2019-08-29       Impact factor: 3.006

9.  Psychosomatic Disorders in Patients with Gastrointestinal Diseases: Single-Center Cross-Sectional Study of 1186 Inpatients.

Authors:  Lijuan Feng; Zichun Li; Xuerong Gu; Jiahui Jiang; Xiaowei Liu
Journal:  Gastroenterol Res Pract       Date:  2021-05-01       Impact factor: 2.260

10.  Prevalence, Behaviours and Burden of Irritable Bowel Syndrome in Medical Students and Junior Doctors.

Authors:  Pisani Anthea; Farrugia Tiziana; Panzavecchia Francesca; Ellul Pierre
Journal:  Ulster Med J       Date:  2021-02-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.